Montpilier-based secon AI-powered genomic medicine earns a Cambridge-based CONGNICA to create a global leader

SeconA French inventor of AI-powered genomic analysis today announced that it made a specific agreement to achieve it ConjunctaThe UK is out of the Welcome Sangar Institute.

The acquisition has been set to create ”The largest global software is authentic player in the genomics space“, More than 300 labs are serving in more than 30 countries.

“Personalized Medicine Chatting Fast Speed ​​Software Demands Inventive Invention and Continuous Investment in Deep Adult“Said MartinCEO of Seccon. “By integrating the Consistenica world-class team, we have the ability to provide our strongest growth trajectory and market-top software to customers, expert explanations services and our presence in the UK market-a global leader of the Cleanical genomics since Landmark 100,000 genome projects after 100,000 genome projects.The “

Established in 2002, Consistenica, more than 25 private and public labs, including national programs such as England and Hong Kong Genomic Programs, bring clinical skills and experiences.

Established in 2017, Seccon provides an AI-powered genomic analysis platform, clinical decision-supporting equipment, which enables molecular laboratories to provide fast, accurate and scaleable analysis of genetic data for oncology, rare and inherited diseases and infectious diseases.

The acquisition combines the AI-powered platform of Sequon for the next generation sequencing (NGS) analysis with the clinical decision support technology and clinical explanation services. Integrated offers will convert complex genomic data into faster, functional insights, eventually accelerate the diagnosis for families infected with rare diseases and enables more specific, personalized cancer therapies.

This move comes to a critical image of the drug. The cost of a human genome has decreased for hierarchy, creating a data tsunami. For hospitals and labs worldwide, the challenge is no longer producing data, but it is explaining. This ‘barrier to interpretation’ is the single largest obstacle in the supply of personalized Medicine.

“Consenica Genomics has become a supportive partner in England, especially in the proceedings of the rare disease diagnosis through their powerful platform for the entire genome analysis“Said Dr. Richard ScottThe genomics is the CEO of England. “We are hoping to continue this important task with the combined skills of the Sicon team to provide facilities for patientsThe “

This acquisition has arrived during a period of intense organic growth for Sequon, which it was seen that the company doubled its income and its international presence had extended more than three to 30 countries in just 12 months.

This also follows Life and soft acquisition In April, which extended the company’s capacity to multi-emics and virology. This speed, by supercharge Round to fund a 20 million dollarsSikon has enabled the technique of integrating a fragmented market and creating a specific software operating system for clinical genomics revolution.

The combined entity will have a significantly extended global footprint:

• Serve more than 160 customer laboratory in more than 30 countries.
• Comprised of a dedicated team of more than 125 employees.
• In 2025 more than 200,000 patients enable the genomic analysis – three times the increase of 2024.

Sicon is committed to ensure the continuity of service and assistance for all conjunasa customers, who will gain access to an expanded and integrated product portfolio. Sikon Welcome will maintain a meaningful presence in the UK at the Sanger Institute.

“The Consenica Board is proud of the great impact on our technology on healthcare since the beginning of our“Said Dr. Andy Richards CBE, Chairman of Consumerica. “We support this combination with Sicon, believe that their outlook and resources are in the best position to move that legacy and our innovative platform ensures that worldwide patients achieve success and service.The “